Bacterial proteins and peptides in cancer therapy

References

• Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010; 7:163 - 72; http://dx.doi.org/10.1038/nrclinonc.2009.236; PMID: 20101258
   PubMed Web of Science ®Google Scholar
• Fialho AM, Chakrabarty AM. Promiscuous anticancer drugs from pathogenic bacteria: rational versus intelligent drug design. In Emerging Cancer Therapy Microbial Approaches and Biotechnological Tools. Fialho AM, Chakrabarty, AM, Eds. John Wiley, Hoboken, 2010. Pages 181-198.
   Google Scholar
• Lambert GK, Duhme-Klair AK, Morgan T, Ramjee MK. The background, discovery and clinical development of BCR-ABL inhibitors. Drug Discov Today 2013; 18:992 - 1000; http://dx.doi.org/10.1016/j.drudis.2013.06.001; PMID: 23769978
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27:2278 - 87; http://dx.doi.org/10.1200/JCO.2008.20.0766; PMID: 19332717
   PubMed Web of Science ®Google Scholar
• Don AS, Zheng XF. Recent clinical trials of mTOR-targeted cancer therapies. Rev Recent Clin Trials 2011; 6:24 - 35; http://dx.doi.org/10.2174/157488711793980147; PMID: 20868343
   PubMedGoogle Scholar
• Zhang YJ, Duan Y, Zheng XFS. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today 2011; 16:325 - 31; http://dx.doi.org/10.1016/j.drudis.2011.02.008; PMID: 21333749
   PubMed Web of Science ®Google Scholar
• Artega CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER-2 positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012; 9:16 - 32; http://dx.doi.org/10.1038/nrclinonc.2011.177
   Web of Science ®Google Scholar
• Jonsson B, Bergh J. Hurdles in anticancer drug development from a regulatory perspective. Nat Rev Clin Oncol 2012; 9:236 - 43; http://dx.doi.org/10.1038/nrclinonc.2012.14; PMID: 22349015
   PubMed Web of Science ®Google Scholar
• Avner BS, Fialho AM, Chakrabarty AM. Overcoming drug resistance in multi-drug resistant cancers and microorganisms: a conceptual framework. Bioengineered 2012; 3:262 - 70; http://dx.doi.org/10.4161/bioe.21130; PMID: 22750915
   PubMed Web of Science ®Google Scholar
• Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, den Bakker MA, Jaitly N, Martens JW, Luider TM, Foekens JA, et al. Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics 2009; 8:1278 - 94; http://dx.doi.org/10.1074/mcp.M800493-MCP200; PMID: 19329653
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26:127 - 32; http://dx.doi.org/10.1038/nbt1358; PMID: 18183025
   PubMed Web of Science ®Google Scholar
• Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6:734 - 45; http://dx.doi.org/10.1038/nrd2380; PMID: 17690708
   PubMed Web of Science ®Google Scholar
• Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370:2011 - 9; http://dx.doi.org/10.1016/S0140-6736(07)61865-0; PMID: 18083403
   PubMed Web of Science ®Google Scholar
• Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7:332 - 44; http://dx.doi.org/10.1038/nrc2106; PMID: 17457301
   PubMed Web of Science ®Google Scholar
• Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today 2012; 17:850 - 60; http://dx.doi.org/10.1016/j.drudis.2012.03.002; PMID: 22465171
   PubMed Web of Science ®Google Scholar
• Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discov Today 2013; 18:807 - 17; http://dx.doi.org/10.1016/j.drudis.2013.05.011; PMID: 23726889
   PubMed Web of Science ®Google Scholar
• Ahsan A, Ray D, Ramanand SG, Hegde A, Whitehead C, Rehemtulla A, Morishima Y, Pratt WB, Osawa Y, Lawrence TS, et al. Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization. J Biol Chem 2013; 288:26879 - 86; http://dx.doi.org/10.1074/jbc.M113.492280; PMID: 23897823
   PubMed Web of Science ®Google Scholar
• Meng Y, Sohar I, Sleat DE, Richardson JR, Reuhl KR, Jenkins RB, Sarkar G, Lobel P. Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain. Mol Ther 2014; 22:547 - 53; http://dx.doi.org/10.1038/mt.2013.267; PMID: 24394185
   PubMed Web of Science ®Google Scholar
• Taylor BN, Mehta RR, Yamada T, Lekmine F, Christov K, Chakrabarty AM, Green A, Bratescu L, Shilkaitis A, Beattie CW, et al. Noncationic peptides obtained from azurin preferentially enter cancer cells. Cancer Res 2009; 69:537 - 46; http://dx.doi.org/10.1158/0008-5472.CAN-08-2932; PMID: 19147567
   PubMed Web of Science ®Google Scholar
• Bizzarri AR, Santini S, Coppari E, Bucciantini M, Di Agostino S, Yamada T, Beattie CW, Cannistraro S. Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy. Int J Nanomedicine 2011; 6:3011 - 9; http://dx.doi.org/10.2147/IJN.S26155; PMID: 22162658
   PubMed Web of Science ®Google Scholar
• Yamada T, Mehta RR, Lekmine F, Christov K, King ML, Majumdar D, Shilkaitis A, Green A, Bratescu L, Beattie CW, et al. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells. Mol Cancer Ther 2009; 8:2947 - 58; http://dx.doi.org/10.1158/1535-7163.MCT-09-0444; PMID: 19808975
   PubMed Web of Science ®Google Scholar
• Mehta RR, Yamada T, Taylor BN, Christov K, King ML, Majumdar D, Lekmine F, Tiruppathi C, Shilkaitis A, Bratescu L, et al. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt. Angiogenesis 2011; 14:355 - 69; http://dx.doi.org/10.1007/s10456-011-9220-6; PMID: 21667138
   PubMed Web of Science ®Google Scholar
• Mehta RR, Hawthorne M, Peng X, Shilkaitis A, Mehta RG, Beattie CW, Das Gupta TK. A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesions. Cancer Prev Res (Phila) 2010; 3:1351 - 60; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0024; PMID: 20841487
   PubMed Web of Science ®Google Scholar
• Richards JM, Warso MA, Mehta D, Christov K, Schaeffer C, Rae Bressler L, Yamada T, Majumdar D, Kennedy SA, Beattie CW, et al. A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors. J Clin Oncol 2011; 29: abstract 2511 (ASCO Annual Meeting).
   Google Scholar
• Fialho AM, Chakrabarty AM. Patent controversies and court cases: cancer diagnosis, therapy and prevention. Cancer Biol Ther 2012; 13:1229 - 34; http://dx.doi.org/10.4161/cbt.21958; PMID: 22954683
   PubMed Web of Science ®Google Scholar
• Warso MA, Richards JM, Mehta D, Christov K, Schaeffer C, Rae Bressler L, Yamada T, Majumdar D, Kennedy SA, Beattie CW, et al. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br J Cancer 2013; 108:1061 - 70; http://dx.doi.org/10.1038/bjc.2013.74; PMID: 23449360
   PubMed Web of Science ®Google Scholar
• Choudhary S, Mathew M, Verma RS. Therapeutic potential of anticancer immunotoxins. Drug Discov Today 2011; 16:495 - 503; http://dx.doi.org/10.1016/j.drudis.2011.04.003; PMID: 21511052
   PubMed Web of Science ®Google Scholar
• Fialho AM, Salunkhe P, Manna S, Mahali S, Chakrabarty AM. Glioblastoma multiforme: novel therapeutic approaches. ISRN Neurol 2012; 2012:642345; http://dx.doi.org/10.5402/2012/642345; PMID: 22462021
   PubMedGoogle Scholar
• Feun L, Tien Kuo M, You M, Wu CJ, Wangpaichitr M, Savaraj N. Arginine deiminase and cancer therapy. In Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools. Fialho AM, Chakrabarty AM, Eds. John Wiley, Hoboken, 2010. Pages 199-217.
   Google Scholar
• Yamada T, Fialho AM, Punj V, Bratescu L, Das Gupta TK, Chakrabarty AM. Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity. Cell Microbiol 2005; 7:1418 - 31; http://dx.doi.org/10.1111/j.1462-5822.2005.00567.x; PMID: 16153242
   PubMed Web of Science ®Google Scholar
• Yamada T, Hiraoka Y, Ikehata M, Kimbara K, Avner BS, Das Gupta TK, Chakrabarty AM. Apoptosis or growth arrest: Modulation of tumor suppressor p53’s specificity by bacterial redox protein azurin. Proc Natl Acad Sci U S A 2004; 101:4770 - 5; http://dx.doi.org/10.1073/pnas.0400899101; PMID: 15044691
   PubMed Web of Science ®Google Scholar
• Fialho AM, Stevens FJ, Das Gupta TK, Chakrabarty AM. Beyond host-pathogen interactions: microbial defense strategy in the host environment. Curr Opin Biotechnol 2007; 18:279 - 86; http://dx.doi.org/10.1016/j.copbio.2007.04.001; PMID: 17451932
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Y, Xia L, Zhang X, Ding X, Yan F, Wu F. Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein. Appl Environ Microbiol 2012; 78:7603 - 10; http://dx.doi.org/10.1128/AEM.01390-12; PMID: 22923405
   PubMed Web of Science ®Google Scholar
• Micewicz ED, Jung C-L, Schaue D, Luong H, McBride WH, Ruchala P. Small azurin derived peptide targets ephrin receptors for radiotherapy. Int J Pept Res Ther 2011; 17:247 - 57; http://dx.doi.org/10.1007/s10989-011-9265-9
   Web of Science ®Google Scholar
• Cho JH, Lee MH, Cho YJ, Park BS, Kim S, Kim GC. The bacterial protein azurin enhances sensitivity of oral squamous carcinoma cells to anticancer drugs. Yonsei Med J 2011; 52:773 - 8; http://dx.doi.org/10.3349/ymj.2011.52.5.773; PMID: 21786442
   PubMed Web of Science ®Google Scholar
• Yang D-S, Miao XD, Ye ZM, Feng J, Xu RZ, Huang X, Ge FF. Bacterial redox protein azurin induce apoptosis in human osteosarcoma U2OS cells. Pharmacol Res 2005; 52:413 - 21; http://dx.doi.org/10.1016/j.phrs.2005.06.002; PMID: 16026999
   PubMed Web of Science ®Google Scholar
• Chaudhari A, Mahfouz M, Fialho AM, Yamada T, Granja AT, Zhu Y, Hashimoto W, Schlarb-Ridley B, Cho W, Das Gupta TK, et al. Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth. Biochemistry 2007; 46:1799 - 810; http://dx.doi.org/10.1021/bi061661x; PMID: 17249693
   PubMed Web of Science ®Google Scholar
• Bernardes N, Ribeiro AS, Abreu S, Mota B, Matos RG, Arraiano CM, Seruca R, Paredes J, Fialho AM. The bacterial protein azurin impairs invasion and FAK/Src signaling in P-cadherin-overexpressing breast cancer cell models. PLoS One 2013; 8:e69023; http://dx.doi.org/10.1371/journal.pone.0069023; PMID: 23894398
   PubMed Web of Science ®Google Scholar
• Paredes J, Albergaria A, Oliveira JT, Jerónimo C, Milanezi F, Schmitt FC. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 2005; 11:5869 - 77; http://dx.doi.org/10.1158/1078-0432.CCR-05-0059; PMID: 16115928
   PubMed Web of Science ®Google Scholar
• Albergaria A, Ribeiro AS, Vieira AF, Sousa B, Nobre AR, Seruca R, Schmitt F, Paredes J. P-cadherin role in normal breast development and cancer. Int J Dev Biol 2011; 55:811 - 22; http://dx.doi.org/10.1387/ijdb.113382aa; PMID: 22161837
   PubMed Web of Science ®Google Scholar
• Hua H, Li M, Luo T, Yin Y, Jiang Y. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 2011; 68:3853 - 68; http://dx.doi.org/10.1007/s00018-011-0763-x; PMID: 21744247
   PubMed Web of Science ®Google Scholar
• Mannello F, Tonti GA, Medda V, Pederzoli A, Sauter ER. Increased shedding of soluble fragments of P-cadherin in nipple aspirate fluids from women with breast cancer. Cancer Sci 2008; 99:2160 - 9; http://dx.doi.org/10.1111/j.1349-7006.2008.00921.x; PMID: 18811693
   PubMed Web of Science ®Google Scholar
• Schlaepfer DD, Mitra SK. Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev 2004; 14:92 - 101; http://dx.doi.org/10.1016/j.gde.2003.12.002; PMID: 15108811
   PubMed Web of Science ®Google Scholar
• Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006; 18:516 - 23; http://dx.doi.org/10.1016/j.ceb.2006.08.011; PMID: 16919435
   PubMed Web of Science ®Google Scholar
• Luo M, Guan JL. Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. Cancer Lett 2010; 289:127 - 39; http://dx.doi.org/10.1016/j.canlet.2009.07.005; PMID: 19643531
   PubMed Web of Science ®Google Scholar
• Avizienyte E, Frame MC. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol 2005; 17:542 - 7; http://dx.doi.org/10.1016/j.ceb.2005.08.007; PMID: 16099634
   PubMed Web of Science ®Google Scholar
• Goel HL, Pursell B, Standley C, Fogarty K, Mercurio AM. Neuropilin-2 regulates α6β1 integrin in the formation of focal adhesions and signaling. J Cell Sci 2012; 125:497 - 506; http://dx.doi.org/10.1242/jcs.094433; PMID: 22302985
   PubMed Web of Science ®Google Scholar
• Bernardes N, Ribeiro AS, Abreu S, Vieira AF, Carreto L, Santos M, Seruca R, Paredes J, Fialho AM. High-throughput molecular profiling of a P-cadherin overexpressing breast cancer model reveals new targets for the anti-cancer bacterial protein azurin. Int J Biochem Cell Biol 2014; 50:1 - 9; http://dx.doi.org/10.1016/j.biocel.2014.01.023; PMID: 24509127
   PubMed Web of Science ®Google Scholar
• Ohlson S. Designing transient binding drugs: a new concept for drug discovery. Drug Discov Today 2008; 13:433 - 9; http://dx.doi.org/10.1016/j.drudis.2008.02.001; PMID: 18468561
   PubMed Web of Science ®Google Scholar
• Shaji J, Patole V. Protein and Peptide drug delivery: oral approaches. Indian J Pharm Sci 2008; 70:269 - 77; http://dx.doi.org/10.4103/0250-474X.42967; PMID: 20046732
   PubMed Web of Science ®Google Scholar
• Eldor R, Arbit E, Corcos A, Kidron M. Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PLoS One 2013; 8:e59524; http://dx.doi.org/10.1371/journal.pone.0059524; PMID: 23593142
   PubMed Web of Science ®Google Scholar
• Kohli N, Westerveld DR, Ayache AC, Verma A, Shil P, Prasad T, Zhu P, Chan SL, Li Q, Daniell H. Oral delivery of bioencapsulated proteins across blood-brain and blood-retinal barriers. Mol Ther 2014; 22:535 - 46; http://dx.doi.org/10.1038/mt.2013.273; PMID: 24281246
   PubMed Web of Science ®Google Scholar
• Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Muñoz ET, Solorio-Meza SE, Amato D, Duran G, Giona F, et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011; 118:5767 - 73; http://dx.doi.org/10.1182/blood-2011-07-366955; PMID: 21900191
   PubMed Web of Science ®Google Scholar
• Timmis K, de Lorenzo V, Verstraete W, Garcia JL, Ramos JL, Santos H, Economidis I, Nogales B, Timmis JK, Fonseca C, et al. Pipelines for New Chemicals: a strategy to create new value chains and stimulate innovation-based economic revival in Southern European countries. Environ Microbiol 2014; 16:9 - 18; http://dx.doi.org/10.1111/1462-2920.12337; PMID: 24387039
   PubMed Web of Science ®Google Scholar
• Fialho AM, Chakrabarty AM. The role and importance of intellectual property generation and protection in drug development. In Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools. Fialho AM, Chakrabarty AM, Eds. John Wiley, Hoboken, 2010. Pages 405-419.
   Google Scholar